Sign In
Buy PFE
$25.36
-0.200 (-0.783%)
At Close: Jun 03, 2026
Why Pfizer Remains A Strong Buy In 2026
10:46am, Friday, 27'th Mar 2026
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of T
Why the Market Dipped But Pfizer (PFE) Gained Today
06:46pm, Thursday, 26'th Mar 2026
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day.
Income Investors Face a Hard Truth About Pfizer's Payout Safety
07:55am, Thursday, 26'th Mar 2026
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors.
Pfizer Inc. $PFE Stake Lifted by First Bank & Trust
05:16am, Thursday, 26'th Mar 2026
First Bank and Trust lifted its stake in shares of Pfizer Inc. (NYSE: PFE) by 21.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC)
Is Pfizer Stock a Buy After This Win?
06:00pm, Wednesday, 25'th Mar 2026
Pfizer's recent phase 2 win was encouraging, but not yet a slam dunk. The company could make significant clinical and regulatory progress in the next few years.
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
12:23pm, Wednesday, 25'th Mar 2026
It's rare to get such a massive high-yielder that's also positioning itself for long-term growth.
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade
09:15am, Wednesday, 25'th Mar 2026
Pfizer is reiterated as a Buy, reflecting undervaluation and strong long-term potential despite near-term patent cliffs and macroeconomic uncertainty. PFE's robust drug pipeline, aggressive acquisitio
Pfizer: Time To Buy The Turnaround
02:06am, Wednesday, 25'th Mar 2026
Pfizer remains a compelling value with a Strong Buy rating, driven by robust oncology pipeline progress and the Seagen acquisition. PFE's valuation is highly attractive, trading at a P/E of 8.35 and o
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
10:52am, Tuesday, 24'th Mar 2026
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year.
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
10:00am, Tuesday, 24'th Mar 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday,
Pfizer Reports 73% Lyme Vaccine Efficacy as Trial Results Complicate Outlook
09:39am, Tuesday, 24'th Mar 2026
Pfizer (PFE) is approaching a potentially important inflection point in its post-pandemic reset as early data from its Lyme disease vaccine trial begins to take
Pfizer Stock Is Doing Something It Hasn't Done Since 2022
04:00pm, Monday, 23'rd Mar 2026
Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer investments amid uncertainty.
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
10:35am, Monday, 23'rd Mar 2026
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
09:36am, Monday, 23'rd Mar 2026
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul
